Intima Bioscience, Inc. Report issue

For profit Phase 2
Founded: New Castle Delaware United States (2015)

Organization Overview

First Clinical Trial
2020
NCT04426669
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Intima Bioscience, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Digestive System Neoplasms (Phase 2)

Gallbladder Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 6